Pfizer to acquire a menopause biotech within 12 months
Resolves: Pfizer announces a definitive acquisition agreement for a company primarily developing menopause-related therapeutics with a transaction value exceeding $500 million.
user-generated· event
Pfizer to acquire a menopause biotech within 12 months
Market overview
Pfizer's strategic shift toward women's health and its $43 billion cash reserves position it to acquire a mid-stage menopause-focused biotech by mid-2027. Competitive pressure from rival deals in the space will accelerate this timeline.
event prediction market
- Implied probability (Yes)
- 70%
- Closes
- 2027-07-12
About this prediction
Resolution criteria
Pfizer announces a definitive acquisition agreement for a company primarily developing menopause-related therapeutics with a transaction value exceeding $500 million.
Source: user-generated
More event markets
- Will HCAC announce LOI by 2026-12-31? — 25% Yes
- Will PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. (PAXH) (CIK 0001350156) file a follow-up 10-Q amendment within 90 days? — 25% Yes
- Will Venyra announce a strategic partnership by 2026-12-31? — 60% Yes
- Will the CEO's line of credit be fully drawn? — 85% Yes
- Will enGene announce a new partnership or licensing deal before Q1 2027? — 50% Yes
- Will Where Food Comes From, Inc. (WFCF) (CIK 0001360565) file a follow-up 10-Q amendment within 90 days? — 25% Yes
- Will Rubrik, Inc. (RBRK) (CIK 0001943896) file a follow-up 10-Q amendment within 90 days? — 25% Yes
- Will Pharma-Bio Serv, Inc. (PBSV) (CIK 0001304161) file a follow-up 10-Q amendment within 90 days? — 25% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…